Viral hepatitis

American Liver Foundation Hosts the 31st Annual Irwin M. Arias Symposium

Retrieved on: 
Thursday, November 3, 2022
Cell Press, Population, Gastroenterology, NAFLD, Metabolism, American Liver Foundation, Patient, Bile, Cancer, Hepatitis C, ALF, Symposium, National, Biomedical engineering, Danny Howells, MIT, Institute, Ageing, Liver, Science, Wolfram Goessling, Education, Viral hepatitis, Digestion, Massachusetts General Hospital, National Institutes of Health, National Institute, CEO, Research, Leadership, Longevity, Glycogen, Goal, Development, Blood, Circadian clock, Liver disease, Institute of Liver and Biliary Sciences, Football, Engineering, Biology, Collection, Diagnosis, Obesity, Hospital, NIH, Physician, Fatty liver disease, Life, Rib cage, Degenerative disease, Disease, Medicine, Dietary supplement, Pharmaceutical industry, MD

FAIRFIELD, N.J., Nov. 3, 2022 /PRNewswire/ -- The American Liver Foundation is pleased to host its 31st annual Irwin M. Arias Symposium, Bridging Basic Science and Liver Disease, on November 10th from 9AM to 5PM ET. This one-day virtual program brings together hundreds of leading biomedical scientists and physicians from across the globe and is designed to bridge the remarkable advances in basic biology and engineering with the understanding of liver diseases and their treatment.

Key Points: 
  • Virtual event, Bridging Basic Science and Liver Disease, brings together hundreds of leading biomedical scientists and physicians from across the globe
    FAIRFIELD, N.J., Nov. 3, 2022 /PRNewswire/ -- The American Liver Foundation is pleased to host its 31st annual Irwin M. Arias Symposium , Bridging Basic Science and Liver Disease,on November 10th from 9AM to 5PM ET.
  • Registration is free alfevents.org/ariassymposium
    "We are honored to host our 31st annual Arias Symposium and are so grateful to Dr. Irwin M. Arias , who is recognized throughout the world, for his lifetime of leadership in bridging the gap between scientists in the lab and physicians in the clinic," said Lorraine Stiehl, CEO, American Liver Foundation.
  • The American Liver Foundation is the nation's largest non-profit organization focused solely on promoting liver health and disease prevention.
  • The mission of the American Liver Foundation isto promote education, advocacy, support services and research for the prevention, treatment and cure of liver disease.

Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2022 Financial Results

Retrieved on: 
Wednesday, November 2, 2022
Security (finance), MAD, HBsAg, CEO, MBA, U.S. Securities and Exchange Commission, Doctor of Philosophy, GLOBE, Board, Liver disease, Nasdaq, COVID-19, Degenerative disease, R, Research, G&A, Ritonavir, Safety, Terminology, NASH, Viral hepatitis, Fatty liver disease, Hyperlipidemia, SRC, Private Securities Litigation Reform Act, Hepatitis, SAD, Therapy, Evaluation, ASO, AASLD, CAM, Drug development, SAN, Sirna, Forward-looking statement, Non-alcoholic fatty liver disease, Institute of Liver and Biliary Sciences, Pharmaceutical industry, Vaccine, Jacob Aligo, HBeAg, CHB

SOUTH SAN FRANCISCO, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today reported recent business progress and financial results for the third quarter, September 30, 2022.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today reported recent business progress and financial results for the third quarter, September 30, 2022.
  • We continue to make important progress in advancing our portfolio of drug candidates targeting chronic hepatitis B (CHB), COVID-19, and NASH, said Lawrence Blatt, PhD, MBA, Chairman and CEO of the Board at Aligos.
  • The emerging safety and anti-lipid activity data appear favorable and support advancing this drug into phase 2 development.
  • As with our development programs, our discovery projects are also making important progress, said Leonid Beigelman, PhD, President of Aligos.

HepVu and NASTAD Release Inaugural Viral Hepatitis Surveillance Status Report

Retrieved on: 
Tuesday, October 25, 2022
Viral hepatitis, Emory, HIV/AIDS, Center, CFAR, Associate, CDC, Doctor of Philosophy, Disease, AIDS, Gilead Sciences, Q&A, Research, Public health, Epidemic, HIV, Association, Emory University, GLOBE, Hepatitis B, Korea Disease Control and Prevention Agency, Partnership, Vaccine, Pharmaceutical industry, Epidemiology

This inaugural viral hepatitis surveillance status report benchmarks the state of viral hepatitis surveillance in the U.S. prior to funding dissemination and establishes a baseline to monitor changes over time as additional resources are allocated.

Key Points: 
  • This inaugural viral hepatitis surveillance status report benchmarks the state of viral hepatitis surveillance in the U.S. prior to funding dissemination and establishes a baseline to monitor changes over time as additional resources are allocated.
  • Im thrilled this report is now available to health departments, researchers, advocates, and other viral hepatitis community members to use as they talk to local leaders, departmental decision makers, and policymakers about why we need more attention on and resources for viral hepatitis surveillance to ultimately impact our efforts in eliminating viral hepatitis in the U.S.
    For the full report and additional insights, download the report here and share our infographics or read an expert Q&A about viral hepatitis surveillance.
  • This inaugural viral hepatitis surveillance status report benchmarks the state of viral hepatitis surveillance in the U.S. prior to funding dissemination, establishes a baseline to monitor changes over time as federal resources are allocated, assesses how jurisdictions across the U.S. are measuring the impact of viral hepatitis on their communities, and highlights areas in need of additional resources.
  • The report , and future report updates, can be used to:
    Monitor progress and trends in viral hepatitis surveillance practices nationally and by jurisdiction;
    Inform advocacy efforts to increase viral hepatitis surveillance funding and resources;
    HepVu and NASTAD collaborated to create this first-ever viral hepatitis surveillance status report.

Aligos Therapeutics to Present Nonclinical and Clinical Data for its Chronic Hepatitis B and NASH Portfolio at AASLD’s The Liver Meeting® 2022

Retrieved on: 
Friday, October 21, 2022
Degenerative disease, SAN, Pharmacology, Doctor of Philosophy, Therapy, Liver disease, Efficiency, Antibody, Liver cancer, Hepatitis B virus, American Association, Association, CEO, Fatty liver disease, Safety, Poster, CAM, American Association for the Study of Liver Diseases, CHB, Drug development, HBsAg, HAP, MBA, Private Securities Litigation Reform Act, NASH, HBeAg, GLOBE, PD-L1, Institute of Liver and Biliary Sciences, CAMS, Hepatitis, Security (finance), Sirna Therapeutics, AAV, Viral hepatitis, Board, U.S. Securities and Exchange Commission, HBV, Terminology, AASLD, Science, EC50, Pharmacodynamics, HBcAg, THR, Patient, RNA, Nasdaq, Sirna, Hyperlipidemia, Toxicity, Liver, Forward-looking statement, PK, COVID-19, Pharmaceutical industry, Vaccine, Pharmacokinetics, Jacob Aligo

All posters, which cover drug candidates targeting chronic hepatitis B (CHB) and nonalcoholic steatohepatitis (NASH), will be available on the Aligos website at Scientific Presentations & Conferences following the conclusion of the conference.

Key Points: 
  • All posters, which cover drug candidates targeting chronic hepatitis B (CHB) and nonalcoholic steatohepatitis (NASH), will be available on the Aligos website at Scientific Presentations & Conferences following the conclusion of the conference.
  • The Liver Meeting 2022 will showcase the breadth and depth of Aligos portfolio of potential treatments for CHB and the continued progress in our NASH program, said Lawrence Blatt, Ph.D., MBA, CEO and Chairman of the Board at Aligos.
  • Data showing the effects of ALG-000184 on HBV DNA, RNA and HBsAg levels are discussed in the poster.
  • First, HAP CAM-1s were shown to induce hepatitis B virus (HBV) core protein (HBc) aggregation and hepatocyte apoptosis in HBc-expressing cells.

Aligos Therapeutics to Announce Third Quarter Results November 2, 2022

Retrieved on: 
Wednesday, October 19, 2022
Degenerative disease, SAN, Institute of Liver and Biliary Sciences, U.S. Securities and Exchange Commission, Therapy, Liver disease, CHB, Drug development, Hepatitis, Security (finance), Fatty liver disease, Nasdaq, Private Securities Litigation Reform Act, NASH, Viral hepatitis, GLOBE, Forward-looking statement, Terminology, Pharmaceutical industry, Jacob Aligo

SOUTH SAN FRANCISCO, Calif., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, the Company), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that it will report the companys third quarter 2022 financial results on Wednesday, November 2, 2022 after the close of the U.S. financial markets.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, the Company), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that it will report the companys third quarter 2022 financial results on Wednesday, November 2, 2022 after the close of the U.S. financial markets.
  • Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases.
  • Aligos is focused on the discovery and development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH).
  • Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.

Aligos Therapeutics to Present Data on pan-Coronavirus Protease Inhibitors for the Treatment of COVID-19 at Cambridge Healthtech Institute’s 20th Annual Discovery on Target Conference, to be Held October 17-20, 2022 in Boston, MA

Retrieved on: 
Tuesday, October 18, 2022
Degenerative disease, SAN, Institute of Liver and Biliary Sciences, U.S. Securities and Exchange Commission, Therapy, Liver disease, Conference, Vaccine, Severe acute respiratory syndrome coronavirus 2, CHB, Drug development, Hepatitis, MBA, Security (finance), Program, Fatty liver disease, Entrepreneurship, Nasdaq, Private Securities Litigation Reform Act, NASH, Trial of the century, Company, Doctor of Philosophy, Viral hepatitis, CEO, GLOBE, Forward-looking statement, Terminology, COVID-19, Pharmaceutical industry, Jacob Aligo

In the presentation, Aligos will review its progress towards the development of broadly-acting, orally available small molecule protease inhibitors to address COVID-19, regardless of the strain.

Key Points: 
  • In the presentation, Aligos will review its progress towards the development of broadly-acting, orally available small molecule protease inhibitors to address COVID-19, regardless of the strain.
  • Rapid evolution of new SARS-CoV-2 variants and the presence of multiple other coronaviruses indicate the need for broadly acting antivirals across all coronaviruses.
  • The SARS-CoV-2 3CL protease (3CLpro) is a clinically validated target and is conserved across coronaviruses.
  • Aligos will review the discovery efforts towards oral pan-coronaviral 3CLpro inhibitors, culminating in the discovery and advancement of ALG-097558.

Target RWE and the American Association for the Study of Liver Diseases Announce Research Agreement for Cirrhosis Quality Collaborative

Retrieved on: 
Tuesday, October 18, 2022
LinkedIn, Master of Science, Health, Data collection, Liver disease, Growth, MSHS, RWD, Data analysis, Patient, Data, Research, Twitter, Entrepreneurship, Target, Chief medical informatics officer, Partnership, Learning, Viral hepatitis, American Association, Association, American Association for the Study of Liver Diseases, Data curation, CQC, Cirrhosis, Institute of Liver and Biliary Sciences, RWE, AASLD, Medical imaging, Pharmaceutical industry, Risk management

DURHAM, N.C., Oct. 18, 2022 /PRNewswire/ -- Today, real world evidence (RWE) leader Target RWE announced a partnership with the American Association for the Study of Liver Diseases (AASLD) to support its Cirrhosis Quality Collaborative (CQC), effective immediately.

Key Points: 
  • DURHAM, N.C., Oct. 18, 2022 /PRNewswire/ -- Today, real world evidence (RWE) leader Target RWE announced a partnership with the American Association for the Study of Liver Diseases (AASLD) to support its Cirrhosis Quality Collaborative (CQC), effective immediately.
  • The CQC is a multi-site network that combines quality improvement and research to optimize the management and outcomes of patients with cirrhosis.
  • "This partnership with Target RWE provides significant value to the CQC and to the liver community.
  • Target RWE brings together the brightest minds in healthcare through an unmatched community of key opinion leaders, patients, and healthcare stakeholders in a collaborative and dynamic model.

Aligos Therapeutics Initiates Dosing In Healthy Volunteers With siRNA Drug Candidate ALG-125755

Retrieved on: 
Friday, October 14, 2022
Degenerative disease, SAN, Institute of Liver and Biliary Sciences, U.S. Securities and Exchange Commission, Doctor of Philosophy, Therapy, Liver disease, CHB, Drug development, HBsAg, Hepatitis, MBA, Security (finance), Fatty liver disease, Nasdaq, Sirna Therapeutics, NASH, Private Securities Litigation Reform Act, Sirna, Viral hepatitis, Board, Pharmacokinetics, CEO, Safety, GLOBE, Forward-looking statement, Terminology, COVID-19, Vaccine, Pharmaceutical industry, Jacob Aligo

SOUTH SAN FRANCISCO, Calif., Oct. 14, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, reported today that dosing with ALG-125755, an siRNA targeting the production of hepatitis B surface antigen (HBsAg), was initiated in healthy volunteers in Study ALG-125755-501 (NCT05561530).

Key Points: 
  • Drugs in this class have generally been well tolerated and have consistently lowered HBsAg levels with more convenient dosing frequencies compared to other injectable HBsAg lowering agents.
  • This is an important first step in the clinical evaluation of the safety, pharmacokinetics, and antiviral activity of ALG-125755, said Matthew W. McClure, M.D., Chief Medical Officer of Aligos.
  • We plan to evaluate single ascending doses across multiple cohorts of healthy volunteers in Q4 2022.
  • Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.

American Liver Foundation Hosts National Legacy Gala Honoring Leaders in Liver Health

Retrieved on: 
Wednesday, October 12, 2022
Institute of Liver and Biliary Sciences, Time, American Liver Foundation, National War Finance Committee, APA Distinguished Scientific Award for an Early Career Contribution to Psychology, Liver disease, Life, Growth, Population, Bile, Science, NAFLD, Infant, Education, Parent, Degenerative disease, Patient, Biotechnology, CNN, Glycogen, Hepatitis, Research, Cancer, Friends, Leadership, Rib cage, AMA Foundation Leadership Award, Obesity, MD, ALF, Blood, CEO, Awareness, Liver, Fatty liver disease, Award, Philip Merrill Award for Outstanding Contributions to Liberal Arts Education, Physician, Child, Viral hepatitis, Football, Digestion, Pharmaceutical industry, Dietary supplement, Auction, Capitales del Fútbol

FAIRFIELD, N.J., Oct. 12, 2022 /PRNewswire/ -- The American Liver Foundation's (ALF) National Legacy Gala will host patients and families, thought leaders, leading medical professionals, business visionaries and organizational partners in the healthcare, pharmaceutical and biotech industries on Thursday, October 13, 2022, at Capitale in New York City all to raise awareness and funds for those affected by liver disease.

Key Points: 
  • "Liver disease affects about 100 million Americans, yet most are unaware they even have it until it's too late," said Lorraine Stiehl, CEO, American Liver Foundation.
  • On behalf of all those affected by liver disease, we extend our sincerest thanks to everyone who has made the National Legacy Gala 2022 possible."
  • The American Liver Foundation is the nation's largest non-profit organization focused solely on promoting liver health and disease prevention.
  • The mission of the American Liver Foundation is to promote education, advocacy, support services and research for the prevention, treatment and cure of liver disease.

Indonesia Diagnostic Labs Market Report 2022: Growing Healthcare Expenditure Fueling Sector Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 5, 2022
Infectious Diseases, Radiology, Hospitals, Health, Prevalence, Hospital, Growth, Population, Diagnosis, CAGR, Typhoid fever, Cancer, Liver cancer, Lung cancer, GDP, Viral hepatitis, Forecast, Competition, Breast cancer, Awareness, Conditional sentence, Diabetes, Degenerative disease, USD, Cervix, Gastroenteritis, Medical imaging, Vaccine

The "Indonesia Diagnostic Labs Market, By Provider Type (Hospital Based Diagnostic Labs, Diagnostic Chains, Stand Alone Diagnostic Labs), By Test Type (Pathology v/s Radiology), By End User, By Region, Competition, Forecast & Opportunities, 2017-2027F" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Indonesia Diagnostic Labs Market, By Provider Type (Hospital Based Diagnostic Labs, Diagnostic Chains, Stand Alone Diagnostic Labs), By Test Type (Pathology v/s Radiology), By End User, By Region, Competition, Forecast & Opportunities, 2017-2027F" report has been added to ResearchAndMarkets.com's offering.
  • Indonesia diagnostic labs market stood at USD 1,997.95 Million in 2021 and is expected to reach a CAGR of 7.84% during the forecast period.
  • Additionally, the growing geriatric population is susceptible to various diseases and requires regular diagnostic checkups for disease diagnosis and treatment, increasing the demand for diagnostic labs.
  • This, in turn, is expected to create lucrative opportunities for the growth of the Indonesia diagnostic labs market during the forecast period.